Details of the Drug Combination

General Information of Drug Combination (ID: DCD8I9I)

• Drug Combination Name: Taxol + Ridaforolimus
• Indication: Malignant melanoma; Status: Investigative [1]
• Component Drugs:
  Taxol (DMUOT9V): Small molecular drug
  Ridaforolimus (DMLHEU7): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: RPMI7951
  Zero Interaction Potency (ZIP) Score: 2.69
  Bliss Independence Score: 2.83
  Loewe Additivity Score: 1.28
  LHighest Single Agent (HSA) Score: 5.1

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Pancreatic cancer	2C10	Phase 3	[4]
Gastric adenocarcinoma	2B72	Phase 2	[5]
Ovarian cancer	2C73	Phase 2	[5]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[2]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[2]

Indication(s) of Ridaforolimus

Disease Entry	ICD 11	Status	REF
Sarcoma	2A60-2C35	Phase 3	[6]

Ridaforolimus Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[7]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCY50IV	ES2	Investigative	[8]
Breast and ovarian cancer syndrome	DCXI2FY	UWB1289+BRCA1	Investigative	[9]
Carcinoma	DCP02CS	OV90	Investigative	[9]
Carcinoma	DC54L7L	EFM192B	Investigative	[9]
Carcinoma	DCSWG7D	MDAMB436	Investigative	[9]
Colon carcinoma	DCTHKEL	RKO	Investigative	[9]
Rectal adenocarcinoma	DC6ICEC	SW837	Investigative	[9]
Adenocarcinoma	DCECDFA	A427	Investigative	[1]
Adenocarcinoma	DCWKYC8	NCIH1650	Investigative	[1]
Adenocarcinoma	DCBII65	NCIH2122	Investigative	[1]
Adenocarcinoma	DCXXNHC	NCIH520	Investigative	[1]
Adenocarcinoma	DCBIJMR	DLD1	Investigative	[1]
Adenocarcinoma	DCSMZJ0	HCT116	Investigative	[1]
Adenocarcinoma	DCTGM32	HT29	Investigative	[1]
Germ cell tumour	DCIUV69	PA1	Investigative	[1]
Large cell lung carcinoma	DC86OV8	NCI-H460	Investigative	[1]
Malignant melanoma	DCIZ5AX	A375	Investigative	[1]
Malignant melanoma	DCDVY4I	HT144	Investigative	[1]
Malignant melanoma	DCZ3QDA	UACC62	Investigative	[1]
Mesothelioma	DCDK86V	MSTO	Investigative	[1]
Ovarian endometrioid adenocarcinoma	DC4HIA9	A2780	Investigative	[1]
Prostate carcinoma	DCAV1OH	LNCAP	Investigative	[1]
Prostate carcinoma	DCA92X7	VCAP	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
• [7] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [8] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [9] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.